Abstract
BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy for women with early breast cancer. This report details longer follow-up with interesting additional time-dependent analyses.
METHODS: National Epirubicin Adjuvant Trial used epirubicin (E) 3-weekly for four cycles followed by classical (c) CMF for four cycles (E-CMF) compared with cCMF for six cycles. BR9601 used E 3-weekly for four cycles followed by CMF 3-weekly for four cycles, compared with CMF 3-weekly for eight cycles.
RESULTS: In all, 2391 eligible patients were randomised and with a median 7.4-year follow-up, E-CMF confirmed a significant benefit over CMF in both relapse-free survival (RFS) (78% vs 71% 5 years RFS, respectively, hazard ratio (HR) = 0.75 (95% CI: 0.65-0.86), P
CONCLUSION: Longer follow-up has confirmed E-CMF as significantly superior to CMF for all patients. Ch17CEP duplication was the only biomarker that demonstrated significant treatment interaction. Standard poor prognostic factors at diagnosis were time-dependent, and after 5 years disease-free, poor prognosis patients demonstrated favourable HRs for survival. British Journal of Cancer (2012) 107, 1257-1267. doi:10.1038/bjc.2012.370 www.bjcancer.com (C) 2012 Cancer Research UK
Original language | English |
---|---|
Pages (from-to) | 1257-1267 |
Number of pages | 11 |
Journal | British Journal of Cancer |
Volume | 107 |
Issue number | 8 |
DOIs | |
Publication status | Published - Sept 2012 |
Keywords / Materials (for Non-textual outputs)
- LIFE
- breast cancer
- NEAT
- THERAPY
- CHEMOTHERAPY
- POSITIVE AXILLARY NODES
- classical CMF
- adjuvant chemotherapy
- epirubicin
- DOXORUBICIN
- anthracyclines
- PREMENOPAUSAL WOMEN